Zacks Investment Research
30 Sept 2026, 22:50 UTC · 2w ago
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
Impact · against what's priced in
The news for Viking Therapeutics is neutral to slightly negative as it reiterates expected losses and a high burn rate that are already anticipated by the market. A Zacks Buy rank provides a modest positive sentiment, but the core financial projections offer no new catalyst for price movement.
- VKTX−0.10
No priced-in read yet
- In context
The projection of -$1 per share earnings and a full-year loss of -$4.47 per share highlights a significant year-over-year decline in EPS and a lack of revenue, though a #2 Zacks Rank suggests some mid-term optimism.
Read from the article alone
Top 1 mover · tap to explore
